Table 3.
Randomized trial | n |
30/120 day stroke or death rate (%) |
CAS excess OR/HR/RR, 95% CI | P | |
---|---|---|---|---|---|
CAS | CEA | ||||
ICSS, 2010∧ (72) | 1,713 | 8.5 | 4.7 | HR 1.86 (1.26–2.74) | 0.001 |
CREST-1, 2010 (65) | 1,321 | 6.0 | 3.2 | HR 1.89 (1.11–3.21) | 0.02 |
SPACE-1, 2006 (73) | 1,183 | 7.7 | 6.5 | OR 1.19 (0.75–1.92)* | 0.4 |
EVA-3S, 2006 (74) | 527 | 9.6 | 3.9 | RR 2.5 (1.2–5.1) | 0.01 |
CAVATAS, 2010# (75) | 504 | 10.0 | 10.0 | OR 1.00 (0.56–1.81)* | 0.98 |
Wallstent, 2001 (76) | 219 | 12.1 | 4.5 | OR 3.00 (1.01–8.61)* | 0.046 |
Bolded font indicates trials with sufficient statistical power to compare the peri-procedural rate of stroke and death with CEA and CAS.
∧120 day event rates.
#90% were symptomatic.
*OR calculated from published raw data.